SCHEMBL26987370

SCHEMBL26987370

CC(C)(C)OC(=O)N1CCCC1c1ccc(-c2cn3c(n2)sc2cc(C(=O)NC4CCOCC4)ccc23)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.51
▸ LMNA P02545 5/20 0.51
▸ TP53 P04637 3/20 0.51
▸ THRB P10828 2/20 0.49
▸ POLB P06746 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ RXFP1 Q9HBX9 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ HPGD P15428 2/20 0.45
▸ ALOX15 P16050 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ EED O75530 1/20 0.40
▸ RBBP4 Q09028 1/20 0.40
▸ SUZ12 Q15022 1/20 0.40
▸ EZH2 Q15910 1/20 0.40
▸ AEBP2 Q6ZN18 1/20 0.40
▸ SLC2A1 P11166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30722043 1.00 MAPT (0.51) MAPTLMNATP53THRBPOLB
SCHEMBL30722105 0.93 MAPT (0.48) MAPTLMNATP53THRBPOLB
SCHEMBL31290640 0.93 MAPT (0.48) MAPTLMNATP53THRBPOLB
SCHEMBL26987614 0.93 MAPT (0.48) MAPTLMNATP53THRBPOLB
SCHEMBL26987190 0.93 MAPT (0.49) MAPTLMNATP53THRBPOLB
SCHEMBL30722236 0.93 MAPT (0.49) MAPTLMNATP53THRBPOLB
SCHEMBL31290623 0.93 MAPT (0.52) MAPTLMNATP53THRBPOLB
SCHEMBL31290650 0.93 MAPT (0.52) MAPTLMNATP53THRBPOLB
SCHEMBL31290610 0.93 MAPT (0.52) MAPTLMNATP53THRBPOLB
SCHEMBL30722124 0.93 MAPT (0.52) MAPTLMNATP53THRBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404283-B2 c-MYC mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-09-02 — — US disclosed
US-20250129100-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-24 — — US disclosed
WO-2024010762-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 — — WO disclosed
WO-2024010762-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129100-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 MAPT 3215/4885LMNA 1484/4885TP53 96/4885
US-12404283-B2 c-MYC mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 MAPT 3215/4885LMNA 1484/4885TP53 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback